» Articles » PMID: 24466413

Regulation of Gene Expression by 1,25-dihydroxyvitamin D3 in Bone Cells: Exploiting New Approaches and Defining New Mechanisms

Overview
Journal Bonekey Rep
Date 2014 Jan 28
PMID 24466413
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The biological actions of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) serve both to orchestrate calcium and phosphorus homeostasis in higher vertebrates and to regulate a diverse set of cellular functions unrelated to control of mineral metabolism. With regard to bone, mesenchymal lineage cells, including both early and late osteoblasts as well as osteocytes represent classic targets of the vitamin D hormone. Accordingly, much of the early information regarding our current understanding of the mechanism of action of 1,25(OH)2D3, of which gene regulation is central, derives from a broad array of studies in these cell types. Indeed, a gene that provided both the earliest and perhaps the most extensive information regarding this and additional mechanisms was that of osteoblast-specific osteocalcin. Subsequent work has provided much additional detail as to how 1,25(OH)2D3, through the vitamin D receptor (VDR), mediates the modulation of many bone cell genes. In recent years, however, a series of technical advances involving the coupling of chromatin immunoprecipitation (ChIP) to unbiased methodologies that involve next-generation DNA sequencing techniques (ChIP-seq) have opened new avenues in the study of gene regulation. In this review, we summarize early work and then focus on more recent studies that have used ChIP-seq analysis and other approaches to provide insight into not only the regulation of specific genes such as the VDR, TNFSF11 (RANKL), LRP5, CBS and CYP24a1, but overarching genome-wide principles of gene regulation as well. The results of these studies highlight the value of these new approaches and the increased insight that can be gained.

Citing Articles

Vitamin D, Th17 Lymphocytes, and Breast Cancer.

Filip-Psurska B, Zachary H, Strzykalska A, Wietrzyk J Cancers (Basel). 2022; 14(15).

PMID: 35954312 PMC: 9367508. DOI: 10.3390/cancers14153649.


Vitamin D Protects against Traumatic Brain Injury via Modulating TLR4/MyD88/NF-B Pathway-Mediated Microglial Polarization and Neuroinflammation.

Jiang H, Yang X, Wang Y, Zhou C Biomed Res Int. 2022; 2022:3363036.

PMID: 35872863 PMC: 9307360. DOI: 10.1155/2022/3363036.


New Approaches to Assess Mechanisms of Action of Selective Vitamin D Analogues.

Pike J, Meyer M Int J Mol Sci. 2021; 22(22).

PMID: 34830234 PMC: 8619157. DOI: 10.3390/ijms222212352.


Osteocytes and Cancer.

Pin F, Prideaux M, Bonewald L, Bonetto A Curr Osteoporos Rep. 2021; 19(6):616-625.

PMID: 34773212 PMC: 8963429. DOI: 10.1007/s11914-021-00712-9.


New developments in our understanding of vitamin metabolism, action and treatment.

Christakos S, Li S, De La Cruz J, Bikle D Metabolism. 2019; 98:112-120.

PMID: 31226354 PMC: 6814307. DOI: 10.1016/j.metabol.2019.06.010.


References
1.
Eberhardt R, Forgione M, Cap A, Leopold J, Rudd M, Trolliet M . Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000; 106(4):483-91. PMC: 380245. DOI: 10.1172/JCI8342. View

2.
Joshi S, Pantalena L, Liu X, Gaffen S, Liu H, Rohowsky-Kochan C . 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011; 31(17):3653-69. PMC: 3165548. DOI: 10.1128/MCB.05020-11. View

3.
Sone T, Ozono K, Pike J . A 55-kilodalton accessory factor facilitates vitamin D receptor DNA binding. Mol Endocrinol. 1991; 5(11):1578-86. DOI: 10.1210/mend-5-11-1578. View

4.
Carlberg C . Molecular basis of the selective activity of vitamin D analogues. J Cell Biochem. 2003; 88(2):274-81. DOI: 10.1002/jcb.10337. View

5.
Zierold C, Darwish H, DeLuca H . Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J Biol Chem. 1995; 270(4):1675-8. DOI: 10.1074/jbc.270.4.1675. View